Common Treatment Approaches for JPD
At a Glance
Juvenile Paget disease treatment is individualized because the condition is extremely rare. Doctors commonly use IV bisphosphonates, but must check and optimize calcium, vitamin D, phosphate, magnesium, and kidney function to reduce dangerous mineral problems.
Treating Juvenile Paget Disease (JPD) is a delicate balancing act. Because JPD is ultra-rare, there are no official, one-size-fits-all pediatric guidelines [1]. Instead, your child’s medical team will use an “empirical” approach—meaning they use the best available research and their clinical experience to tailor a treatment plan specifically for your child [1][2].
The primary goal of treatment is to slow down the rapid remodeling of the bones, which has been reported to help reduce pain, prevent fractures, and protect your child’s ability to move and grow [2][3].
Common Treatment Approaches: Intravenous Bisphosphonates
The most common treatment approach for JPD involves a class of medications called bisphosphonates, usually given through an intravenous (IV) infusion. These drugs work by settling into the bone and acting as a “lock” that prevents bone-breaking cells (osteoclasts) from being overactive [4][1].
- Pamidronate: This is often the first choice for many specialists. It is typically given in individualized cycles throughout the year. Research has shown that children on pamidronate often experience pain relief and improved motor development [2][5].
- Zoledronate: This is a more potent, long-acting bisphosphonate. It may be used if pamidronate is no longer effective or if a more powerful response is needed [6]. While effective at lowering alkaline phosphatase (ALP) levels, it carries a known, significant risk of causing a severe, sudden drop in blood calcium [6][7].
The Critical “Pre-Treatment” Phase
Before your child can receive their first infusion, their body must be prepared. This is perhaps the most important safety step in JPD care.
Because your child’s body may be relying heavily on “recycling” calcium from their bones to keep their blood calcium levels stable, a sudden halt in bone breakdown can cause blood calcium to plummet dangerously low (hypocalcemia) [8][6][9].
Before any infusion, your doctor will check blood levels of calcium, phosphate, magnesium, vitamin D, and kidney function [7][9].
Based on these labs, the treating team will prescribe specific doses of calcium and vitamin D supplements in the days or weeks leading up to treatment to “prime” their system [9][8]. You must strictly follow the treating team’s instructions for these supplements and never start or adjust the doses on your own.
Severe hypocalcemia can cause muscle spasms, tingling in the hands and face, or even seizures and heart rhythm issues [10][11]. If your child is at high risk, they may need to stay in the hospital for monitoring and IV calcium during their first few treatments [6].
Exploring Other Options: Denosumab
In cases where bisphosphonates are not working well, doctors may consider an “off-label” medication called denosumab [12]. Denosumab works in the bloodstream to block the signal that turns on bone-breaking cells [1][13].
Pediatric evidence for denosumab in JPD is extremely limited, and it carries unique risks:
- Mineral Imbalance: It can cause severe drops in calcium and phosphate shortly after the injection [14][15].
- Rebound Hypercalcemia: When denosumab wears off, the “brakes” it provides are released all at once. This can cause bone breakdown to surge, leading to dangerously high levels of calcium in the blood (hypercalcemia), which can damage the kidneys [16].
If your child is prescribed denosumab, a family must never stop, delay, or change denosumab without a specialist’s explicit transition plan to monitor for these risks.
Long-Term Outlook and Goals
Treatment for JPD is highly individualized and may be a long-term commitment, balancing symptom relief against uncertain long-term effects [1][2].
Progress is monitored by observing improvements in pain, tracking height and motor development, assessing X-rays, and checking ALP and other labs [2][6]. Note that any growth abnormalities may reflect the JPD itself, overall health, or uncertain treatment effects; bisphosphonates are not known to definitively impair growth [17]. It is important to know that while treatment is aimed at helping the bones, it may not prevent all complications, such as hearing loss, which is why a specialized, multi-disciplinary care team is essential [2][3].
Common questions in this guide
What is the usual first treatment for Juvenile Paget disease?
Why are calcium and vitamin D checked before a bisphosphonate infusion?
What symptoms could signal low calcium after an infusion?
Is denosumab used to treat Juvenile Paget disease?
How will doctors tell whether treatment is helping?
Can Juvenile Paget disease treatment affect growth or hearing?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Treatment options
Would an intravenous bisphosphonate be an option for my child, and why?
Safety lab tests
Which blood levels would you check, such as calcium and vitamin D, for my child's safety?
Progress monitoring
How would you monitor my child's progress over time?
Get notified when new evidence is published on Juvenile Paget disease.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (17)
- 1
Juvenile Paget disease.
Polyzos SA, Cundy T, Mantzoros CS
Metabolism: clinical and experimental 2018; (80()):15-26 doi:10.1016/j.metabol.2017.10.007.
PMID: 29080812 - 2
Clinical course in two children with Juvenile Paget's disease during long-term treatment with intravenous bisphosphonates.
Höppner J, Steff K, Misof BM, et al.
Bone reports 2021; (14()):100762 doi:10.1016/j.bonr.2021.100762.
PMID: 33850973 - 3
Juvenile Paget's Disease: Report of a successful treatment throughout the complete growth of a patient with a missense TNFRSF11B mutation.
Prata AR, Saraiva J, Salgado M, Estanqueiro P
Joint bone spine 2021; (88(6)):105243 doi:10.1016/j.jbspin.2021.105243.
PMID: 34166796 - 4
Genetic disorders associated with the RANKL/OPG/RANK pathway.
Xue JY, Ikegawa S, Guo L
Journal of bone and mineral metabolism 2021; (39(1)):45-53 doi:10.1007/s00774-020-01148-4.
PMID: 32940787 - 5
Early-onset juvenile Paget disease associated with a homozygous intronic TNFRSF11B variant: a 2-year follow-up.
Meral R, Gökoğlu M
Journal of pediatric endocrinology & metabolism : JPEM 2026; doi:10.1515/jpem-2026-0332.
PMID: 42528457 - 6
Acquired resistance to pamidronate treated effectively with zoledronate in juvenile Paget's disease.
Gonc EN, Ozon A, Buyukyilmaz G, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2018; (29(6)):1471-1474 doi:10.1007/s00198-018-4443-7.
PMID: 29502293 - 7
Zoledronate.
Reid IR, Green JR, Lyles KW, et al.
Bone 2020; (137()):115390 doi:10.1016/j.bone.2020.115390.
PMID: 32353565 - 8
High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Ishikawa K, Nagai T, Sakamoto K, et al.
Therapeutics and clinical risk management 2016; (12()):1831-1840 doi:10.2147/TCRM.S123172.
PMID: 27980413 - 9
Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Body JJ, Bone HG, de Boer RH, et al.
European journal of cancer (Oxford, England : 1990) 2015; (51(13)):1812-21.
PMID: 26093811 - 10
Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
Park SY, Kim J, Chung HY
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2022; (33(1)):305-308 doi:10.1007/s00198-021-06059-2.
PMID: 34232341 - 11
Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
Uhm SJ, Hall JA, Herrington JD
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2021; (27(5)):1287-1290 doi:10.1177/1078155220964550.
PMID: 33081580 - 12
Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review.
Wang D, Tang X, Shi Q, et al.
Translational pediatrics 2023; (12(3)):470-486 doi:10.21037/tp-22-276.
PMID: 37035391 - 13
Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects.
Raborn LN, Burke AB, Ebb DH, et al.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2021; (32(9)):1889-1893 doi:10.1007/s00198-021-05895-6.
PMID: 33772327 - 14
Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases.
Upfill-Brown A, Bukata S, Bernthal NM, et al.
JBMR plus 2019; (3(10)):e10210 doi:10.1002/jbm4.10210.
PMID: 31687646 - 15
Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document.
Vanderniet JA, Szymczuk V, Högler W, et al.
The Journal of clinical endocrinology and metabolism 2024; (109(5)):1371-1382 doi:10.1210/clinem/dgad657.
PMID: 38041865 - 16
Rebound hypercalcaemia timing is associated with cumulative weight-based denosumab dose for central giant cell granuloma treatment in children despite a dose weaning regimen.
Chesover AD, Allgrove J, Calder A, et al.
Bone 2025; (197()):117501 doi:10.1016/j.bone.2025.117501.
PMID: 40311887 - 17
Rhizomelia and Impaired Linear Growth in a Girl with Juvenile Paget Disease: The Natural History of the Condition.
Höppner J, Steff K, Lobert F, et al.
Hormone research in paediatrics 2021; (94(3-4)):151-158 doi:10.1159/000517164.
PMID: 34261073
This page explains Juvenile Paget disease treatment and safety monitoring for informational purposes only and does not constitute medical advice. Do not change supplements or medicines without your child's specialist's guidance.